Supplementary Table 2. Efficacy outcomes at year 5 (week 240) among HBeAg-positive (study 110) and HBeAg-negative (study 108) participants (OL FAS)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Efficacy endpoints** | **HBeAg-positive participants (study 110)** | | | **HBeAg-negative participants (study 108)** | | |
| n/N or n/n (% | **TAF-TAF**  **(*n* = 133)** | **TDF-TAF**  **(*n*= 52)** | **Proportional difference (95% CI)** | **TAF-TAF**  **(*n* = 99)** | **TDF-TAF**  **(*n* = 47)** | **Proportional difference (95% CI)** |
| HBV DNA <2 9 IU/mL | 103/113 (91.2) | 47/52  (90.4) | 0.3%  (-8.8% –9.3%) | 95/99  (96.0) | 46/47  (97.9) | -3.8%  (-9.3%–1.6%) |
| HBeAg loss\* | 44/108 (40.7) | 17/52  (32.7) | ND | - | - | - |
| HBeAg seroconversion\* | 28/108 (25.9) | 11/52  (21.2) | ND | - | - | - |
| HBsAg loss† | 5/113  (4.4) | 0/52  (0) | ND | 3/99  (3.0) | 0/47  (0) | ND |
| HBsAg seroconversion† | 3/113  (2.7) | 0/52  (0) | ND | 1/99  (1.0) | 0/47 (0) | ND |
| Mean change in HBsAg from baseline, log10IU/mL (SD) | -0.85 (1.230) | -0.76 (1.042) | ND | -0.58 (0.904) | -0.28 (0.591) | ND |
| ALT normalization by China criteria‡ | 82/97 (84.5) | 39/49 (79.6) | 5.1%  (-9.3–19.4% ) | 73/82 (89.0) | 27/33 (81.8) | 6.8%  (-9.9%–23.5%) |
| ALT normalization by the 2018 AASLD criteria§ | 82/104 (78.8) | 40/50 (80.0) | 1.1%  (-15.5%–13.4%) | 72/87 (82.8) | 28/38 (73.7) | 8.2%  (-9.0%–25.4%) |
| Mean FibroTest score change from baseline (SD) | -0.09 （0.147） | -0.12 （0.196） | ND | -0.05 (0.147) | -0.08 (0.163) | ND |

\*Among patients who were seropositive for HBeAg and seronegative for anti-HBe at baseline; †Among patients who were seropositive for HBsAg and seronegative for anti-HBs at baseline; ‡Among patients with ALT above the China criteria (ULN = 40 U/L) at baseline. §Among patients with ALT above the 2018 AASLD criteria (ULN: 35 U/L for males and 25 U/L for females). AASLD, American Association for the Study of Liver Diseases; ALT, alanine aminotransferase; Anti-HBe, hepatitis B e antibody; Anti-HBs, hepatitis B surface antibody; CI, confidence interval; DNA, deoxyribonucleic acid; DXA, dual energy x-ray absorptiometry; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; ND, not done; OL FAS, open-label full analysis set; SD, standard deviation; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. ULN: upper limit of normal.